

## Accepted Manuscript

Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions

P. Chennell, L. Delaborde, M. Wasiak, M. Jouannet, E. Feschet-Chassot, F. Chiambaretta, V. Sautou



PII: S0928-0987(17)30048-9

DOI: doi: [10.1016/j.ejps.2017.01.024](https://doi.org/10.1016/j.ejps.2017.01.024)

Reference: PHASCI 3884

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 9 August 2016

Revised date: 20 January 2017

Accepted date: 21 January 2017

Please cite this article as: P. Chennell, L. Delaborde, M. Wasiak, M. Jouannet, E. Feschet-Chassot, F. Chiambaretta, V. Sautou, Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), doi: [10.1016/j.ejps.2017.01.024](https://doi.org/10.1016/j.ejps.2017.01.024)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**STABILITY OF AN OPHTHALMIC MICELLAR FORMULATION OF CYCLOSPORINE A IN UNOPENED  
MULTIDOSE EYEDROPPERS AND IN SIMULATED USE CONDITIONS**

P. CHENNEL<sup>(1)\*</sup>, L. DELABORDE<sup>(2)</sup>, M. WASIAK<sup>(2)</sup>, M. JOUANNET<sup>(2)</sup>, E. FESCHET-CHASSOT<sup>(1)</sup>, F. CHIAMBARETTA<sup>(3)</sup>, V. SAUTOU<sup>(1)</sup>

(1) UNIVERSITE CLERMONT AUVERGNE, CHU CLERMONT FERRAND, CNRS, SIGMA CLERMONT, ICCF, F-63000 CLERMONT-FERRAND, FRANCE

(2) CHU CLERMONT-FERRAND, POLE PHARMACIE, F-63000 CLERMONT-FERRAND, FRANCE

(3) CHU CLERMONT-FERRAND, SERVICE OPHTALMOLOGIE, F-63000 CLERMONT-FERRAND, FRANCE

\* : corresponding author:

Dr Philip Chennell, Hospital Pharmacist, PharmD MSc

pchennell@chu-clermontferrand.fr

Phone: +(33)4 73 75 10 36

Pôle Pharmacie

CHU Clermont-Ferrand

58 rue Montalembert, BP69

63003 Clermont-Ferrand

FRANCE

**MeSH Keys words:** Ophthalmic; Cyclosporine A; Drug Stability; Pharmaceutical technology, drug preparation

**ABSTRACT**

Cyclosporine A eye drops are used at concentrations ranging from 0.5 to 20 mg/ml to treat a variety of ophthalmic diseases. Cyclosporine A formulations at high concentrations are difficult to manufacture because of cyclosporine's lipophilicity, and generally require an oil based vector. In this study, we investigated the physicochemical and microbiological stability of two high concentrations (10 mg/mL and 20 mg/mL) of an ophthalmic Cyclosporine A micellar solution in a low density polyethylene multidose eyedropper, at two conservation conditions (5°C and 25°C), before and with simulated use. Analyses used were the following: visual inspection, Cyclosporine quantification by a stability-indicating liquid chromatography method, osmolality and pH measurements and turbidity. A complementary analysis by dynamic light scattering was implemented to evaluate potential particle formation or micelle size change. In the in-use study, cyclosporine quantification was also performed on the drops emitted from the multidose eyedroppers. Our results show that the cyclosporine micellar formulation retains good physicochemical and microbiological stability, as all parameters stayed within acceptable range limits, however a higher variability in Cyclosporine concentrations was observed for 20 mg/ml units stored at 25°C. The in-use study showed that Cyclosporine

Download English Version:

<https://daneshyari.com/en/article/5547858>

Download Persian Version:

<https://daneshyari.com/article/5547858>

[Daneshyari.com](https://daneshyari.com)